Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 25Neoplasms 12Prostatic Neoplasms 9Multiple Myeloma 9Neoplasm Metastasis 7Giant Cell Tumor of Bone 7Osteoporosis 4Fractures, Bone 4Recurrence 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Bone Diseases, Metabolic 3Bone Diseases 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Bone Neoplasms 2Bone Metastases 2Bone Cysts, Aneurysmal 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Paraproteinemias 1Pancreatic Neoplasms 1

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Giant Cell Tumors × Denosumab × Clear all
NCT00680992 2022-09-22

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Amgen

Phase 2 Completed
535 enrolled 16 charts

Giant Cell Tumors, Neoplasms, Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡